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Objective: To assess the balance between costs and effects of the sirolimus eluting stent in the treatment of
single native de novo coronary lesions in the RAVEL (randomised study with the sirolimus eluting Bx
Velocity balloon expandable stent in the treatment of patients with de novo native coronary artery lesions)
study.
Design: Multicentre, double blind, randomised trial
Setting: Percutaneous coronary intervention for single de novo coronary lesions
Patients: 238 patients with stable or unstable angina.
Interventions: Randomisation to sirolimus eluting stent or bare stent implantation.
Main outcome measures: Patients were followed up to one year and the treatment effects were expressed
as one year survival free of major adverse cardiac events (MACE). Costs were estimated as the product of
resource utilisation and Dutch unit costs.
Results: At one year, the absolute difference in MACE-free survival was 23% in favour of the sirolimus
eluting stent group. At the index procedure, sirolimus eluting stent implantation had an estimated
additional procedural cost of J1286. At one year, however, the estimated additional cost difference had
decreased to J54 because of the reduction in the need for repeat revascularisations in the sirolimus group
(0.8% v 23.6%; p , 0.01). After adjustment of actual results for the consequences of angiographic follow
up (correction based on data from the BENESTENT (Belgium Netherlands stent) II study), the difference in
MACE-free survival was estimated at 11.1% and the additional one year costs at J166.
Conclusions: The one year data from RAVEL suggest an attractive balance between costs and effects for
sirolimus eluting stents in the treatment of single native de novo coronary lesions. The cost effectiveness of
drug eluting stents in more complex lesion subsets remains to be determined.
S
irolimus eluting stents have been recently proved to
greatly reduce coronary restenosis and the need for
subsequent revascularisation compared with conven-
tional stenting.1–3 Sirolimus eluting stents have been available
for routine use since April 2002 in Europe and since April
2003 in the USA. Owing to the clear clinical superiority of
these devices over bare metal stents, clinicians would be
expected to want to use the new stent as extensively as
possible. However, sirolimus stents are more costly than
conventional bare stents, which may increase up front
procedural costs and has been perceived as an important
limitation to more widespread utilisation of these devices in
clinical practice. On the other hand, the reduction of repeat
intervention procedures during follow up may save costs,
which may eventually lower total costs. Therefore, in the
current era of cost containment policies, the question arises
as to how the additional effects compare with the additional
costs.
The present study addressed this question for patients
included in the RAVEL (randomised study with the sirolimus
eluting Bx Velocity balloon expandable stent in the treatment
of patients with de novo native coronary artery lesions)
study. It is important to note that the RAVEL study had a
protocol mandated angiogram scheduled at 5–7 months of
follow up.1 It is known from the Belgium Netherlands stent
(BENESTENT) II study that this policy may bias both cost
and effectiveness estimates of the treatments when compared
with estimates for patients without routine angiographic
follow up.4 Since routine angiographic follow up is not
standard practice in the ‘‘daily life’’ of most centres, the
question needs to be raised whether the results would differ
without angiographic follow up. This issue was addressed in
this report by an analysis that combined estimates of costs
and effects from the RAVEL study (comparing drug eluting
with bare stents) with estimates of the effect of angiographic
follow up from the BENESTENT II study (comparing results
with and without scheduled angiographic follow up).
MATERIAL AND METHODS
The study protocol and main findings of the RAVEL study
have been reported in detail elsewhere.1 In brief, RAVEL was
a randomised, double blind study of 238 patients with a
diagnosis of stable or unstable angina scheduled for treat-
ment of a single de novo target lesion in a native coronary
vessel. Patients were treated with either a bare metal Bx
Velocity stent (Cordis Corp, Miami Lakes, Florida, USA) or a
Abbreviations: ARTS, arterial revascularisation therapies study;
BENESTENT, Belgium Netherlands stent; DEBATE, Doppler endpoints
balloon angioplasty trial Europe; MACE, major adverse cardiac events;
RAVEL, randomised study with the sirolimus eluting Bx Velocity balloon
expandable stent in the treatment of patients with de novo native
coronary artery lesions
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similar sirolimus eluting Bx Velocity stent. Both stents were
indistinguishable, except under microscopy. At 30 days and
six and 12 months, patients returned for evaluation and were
specifically questioned to identify the possible interim deve-
lopment of angina, as well as to monitor major adverse
cardiac events (MACE) including additional revascularisation
of the index target lesion. Diagnostic angiography was
performed at 180 (range 150–210) days or preceding a
reintervention. The decision to perform a reintervention was
left to the investigator’s discretion, who was asked to register
whether it was based on clinical symptoms or guided by
angiographic results.
Cost effectiveness
Effectiveness was assessed by using the composite of 12
month MACE, which were all-cause death, non-fatal
myocardial infarction, and target lesion revascularisation
(either surgical or percutaneous). With respect to costs, the
analysis was limited to the direct medical costs. The balance
between costs and effects after 12 months was assessed by
computing the incremental cost effectiveness ratio (the
average one year costs per patient treated with drug eluting
stents minus the average one year costs with bare stent
implantation divided by the percentage change in MACE-free
survivors after one year).
For cost effectiveness, two scenarios were investigated. The
first scenario reflects the actual protocol driven resource use
and effectiveness observed in the RAVEL study (which
included a six month angiogram). For the estimation of the
costs and effects of this scenario, we used methods similar to
those used in the assessments of costs and effects in the
BENESTENT II study,4 the DEBATE (Doppler endpoints
balloon angioplasty trial Europe) II study,5 and ARTS (arterial
revascularisation therapies study).6 Resource utilisation data
were collected from the case record form for the initial
procedure (number of balloons, type and number of stents,
type and number of catheters, etc), hospital admissions
(coronary care unit, intensive care unit, conventional ward),
and major treatment and diagnostic procedures after
the initial procedure. Unit costs were estimated, before the
analysis of the data, on the basis of detailed information from
the Erasmus Medical Centre, Rotterdam, the Netherlands,
following an approach similar to that reported previously.7
Costs per patient were calculated as the product of each
patient’s resource utilisation and the corresponding unit cost.
Information about the prices of sirolimus eluting and bare
stents was obtained from the manufacturing company. In
both arms, the medication costs include those of eight weeks
of antiplatelet treatment.
The second scenario excluded follow up angiography as a
standard procedure. The rationale for this approach was to
exclude the effect of the so-called oculostenotic reflex, which
may increase the incidence of repeat intervention in patients
undergoing protocol mandated angiographic re-evaluation.4 8
It is noteworthy that the information collected at the time of
the repeat revascularisations on whether the new interven-
tion was driven by angina was indicative of the effect of
angiographic follow up. However, these records were not
informative about the impact of follow up angiograms on the
number of angiographies and repeat procedures that would
have taken place before and after 5–7 months. It is expected
that some of the procedures performed during the follow up
visit would normally have been carried out during the
months either before or after the protocol driven angiogram.
With respect to the angiograms and interventions that would
have been performed before the prespecified time point, it is
expected that these were postponed knowing that angio-
grams were already scheduled at the 5–7 month follow up.
One would therefore expect a lower revascularisation rate
before a prespecified angiographic follow up than would have
been the case without such a specification. Conversely, if an
angiogram is prespecified, there may be less need for later
angiography and for late repeat procedures than without
angiographic follow up.
In the BENESTENT II study,4 which compared balloon
angioplasty with stenting, a one to one subrandomisation
was carried out assigning patients either to planned angio-
graphic follow up (as in the RAVEL trial) or to clinical follow
up alone (which is preferred for the purpose of a cost
effectiveness analysis). Among patients with protocol man-
dated angiographic follow up, the rate of repeat revascular-
isation was 18.27% (stenting) versus 22.28% (balloon).
Without angiographic follow up, the percentage of repeat
revascularisations was 7.77% versus 16.26%, respectively.
With angiographic follow up, the percentage of patients with
unscheduled angiograms was 8.17% versus 12.86% (with and
without stenting). Without angiographic follow up the
percentage of unscheduled angiograms was 14.08% versus
20.20%. Thus, on average, the inclusion of angiographic
follow up increased the number of repeat revascularisations
by a factor 1.6 and decreased the number of unscheduled
angiograms by a factor of 0.6. The data from the BENESTENT
II trial, therefore, offer a source for estimating the effect of
angiographic follow up on both the occurrence of angiograms
and repeat interventions. Moreover, that trial also offers
information about the timing of these procedures.
To estimate the effects of angiographic follow up on
treatment, the time after the initial procedure was divided
into three periods: firstly, from the index procedure to month
5; secondly, from month 5 to month 7; and thirdly, from
month 7 to month 12. For each period, the rates of non-
scheduled angiographies and of repeat revascularisation were
estimated. Differences were estimated in terms of relative
risk ratios; those significantly different from 1.0 were
included in the analysis. Subsequently, the numbers of
patients free of repeat revascularisations were estimated by
multiplying the number of repeat revascularisations observed
in RAVEL with the relative risk ratios derived from
BENESTENT for all three periods. Finally, average MACE-
free survival was estimated by multiplying the revascularisa-
tion rate times the relative risk scores of patients who only
had repeat revascularisations. Patients who died or had a
myocardial infarction continued to be counted as having had
an event.
A similar procedure was followed with respect to costs. For
this analysis, estimates were needed of the costs associated
with a repeat procedure and the costs of an angiogram, not
only of the procedure itself but also of the additional costs
associated with these procedures. These costs were estimated
by using the data from the RAVEL study and applying a
linear regression analysis with costs as the dependent
variable and the various events as independent variables. It
was noted that the resulting cost estimates were not just for
the cost of the procedure but that they had to be interpreted
as the additional costs associated with the treatment of a
patient who undergoes such procedures. Total costs were
corrected on the basis of the increase in the expected
numbers of non-scheduled angiograms and the expected
decrease in the number of repeat revascularisations.
Statistical analysis
All analyses were based on the intention to treat principle. In
estimating the risk ratios from BENESTENT II, whether these
relative risks differed between the randomised treatments
(stent or balloon) was assessed by testing for differences in
the log transformed risk ratios. Where the hypothesis of a
similar effect could not be rejected (95% significance), data
from both procedures were pooled to estimate the relative
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risks. A correction for the number of angiograms and repeat
procedures was made when the risk ratios differed (95%
significance) from 1.
With respect to the scenario assuming no angiographic
follow up, the uncertainties surrounding the estimate were
addressed by a combination of bootstrapping and multi-
variate sensitivity analysis. In bootstrapping, a number, say
1000, of new trials are simulated of exactly the same size as
the original trial. This is done by drawing patients at random
(with replacement) from the original trial. Each bootstrap
leads to a new estimate of average costs and average effects.
The resulting 1000 estimates can be summarised in terms of a
distribution. Truncating the upper and lower 2.5% provides
the 95% confidence intervals. This is a very convenient
method when the distribution cannot be obtained in a classic
way.9
RESULTS
In total, 120 patients were randomly assigned to sirolimus
eluting stent implantation and 118 patients to bare metal
Table 1 Costs associated with observed resource use
Resource use per patient
Unit cost (J)
Cost (J)
Sirolimus stent
(n = 120)
Bare stent
(n = 118)
Sirolimus stent
(n = 120)
Bare stent
(n = 118) Difference
Index procedure
Procedure time (min) 70.8 70.6 18 1288 1285 3
Study stent 1.03 1.02 2000/672 2050 683 1367
Other stent type 0.02 0.03 712 12 24 212
Guiding catheter 1.10 1.07 98 107 104 3
Guidewire 1.08 1.04 115 124 120 4
Balloon 1.32 1.37 491 646 674 228
Doppler 0.03 0.06 523 13 31 218
IVUS catheter 0.23 0.29 614 143 177 234
Contrast medium 192.08 200.18 1 98 102 24
Procedure related medication 67 63 24
CCU stay (days) 0.30 0.26 963 289 252 37
ICU stay (days) 0.29 0.29 1058 307 305 2
Non-CCU/ICU stay (days) 2.12 2.24 343 727 768 241
Total procedure costs 5872 4588 1284
Follow up
Repeat revascularisation
Repeat PTCA (target and non-target) 0.03 0.31 107 908 2800
CABG (target and non-target) 0.01 0.01 7448 62 126 264
Coronary angiography
Non-scheduled angiographies 0.08 0.10 2160 180 220 240
Protocol angiographies 0.90 0.74 2160 1944 1592 351
Transfusion 0.01 0.01 60 1 1 0
Vascular surgery 0.01 0.02 4341 36 74 237
Emergency room visit 0.15 0.12 44 7 5 1
Observation unit ,24 h after admission 0.02 0.20 193 3 39 236
Outpatient rehabilitation 0.08 0.18 23 2 4 22
CCU stay (days) 0.17 0.64 963 161 612 2452
ICU stay (days) 0.14 0.11 1058 151 117 35
Non-CCU/ICU stay (days) 2.15 2.50 343 737 858 2121
Rehabilitation 0.24 0.37 343 83 128 245
Total follow up costs 3473 4683 21210
Total direct medical cost (excluding medication) 9345 9271 74
Medication 624 644 220
Total direct medical cost (including medication) 9969 9915 54
CABG, coronary artery bypass graft; CCU, coronary care unit; ICU, intensive care unit; IVUS, intravascular ultrasound; PTCA, percutaneous transluminal coronary
angioplasty.
Table 2 Non-scheduled angiograms and repeat revascularisation in the BENESTENT II
trial4
Without angiographic
follow up (angioplasty
with and without stents)
With angiographic follow
up (angioplasty with and
without stents) Relative risk (95% CI)
Months 1–5
Angiograms 8.6% 7.2% 1.192 (0.747 to 1.904)
Repeat revascularisations 6.1% 8.9% 0.691 (0.424 to 1.126)
Months 6–7
Angiograms 3.4% 1.0% 3.577 (1.187 to 10.776)*
Repeat revascularisations 3.4% 4.5% 0.387 (0.212 to 0.704)*
Month 8–12
Angiograms 5.1% 2.4% 2.146 (1.023 to 4.501)*
Repeat revascularisations 2.4% 2.6% 0.929 (0.399 to 2.164)
Differences of log transformed risk ratios were not significant based on the 95% confidence interval (CI)
surrounding these differences.
BENESTENT, Belgium Netherlands stent.
*Significant risk ratio used in RAVEL (randomised study with the sirolimus eluting Bx Velocity balloon expandable
stent in the treatment of patients with de novo native coronary artery lesions) cost effectiveness model.
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stents. With the exception of a higher percentage of men in
the control arm, the two groups had similar baseline and
procedural characteristics. At one year, the sirolimus and bare
stent group had similar mortality (both 1.7%) and myocardial
infarction rates (3.3% v 4.2%, respectively). The one year
incidence of MACE was significantly reduced in the sirolimus
group compared with the controls (5.8% v 28.8%, p , 0.01 by
log rank test), mainly due to a major decrease in the need for
repeat revascularisation in the sirolimus group (0% v 22.9%,
p , 0.01). Table 1 presents the estimates of costs after one
year. It appears that the additional costs of the initial
procedure were almost completely recouped by the decrease
in the costs of follow up. Based on the observed event rates
and overall costs in RAVEL, without correcting for the impact
of protocol mandated follow up angiograms, at the end of the
first year the total costs were estimated to be only J54 per
patient higher in the sirolimus eluting stent group than in the
bare stent group. Costs per MACE-free survivor were
estimated at J234 with an upper 95% limit of J5679.
When considering the results in table 1 it may be noted
that the costs of the scheduled angiograms are higher in the
sirolimus group than in the bare stent group (which is related
to the higher number of patients with repeat procedures in
the bare stent group). This may suggest that without such
follow up, the costs of the initial procedure would have been
completely recouped. However, this suggestion would neglect
the effect of the oculostenotic reflex, since the difference in
repeat percutaneous revascularisation procedures between
the two groups suggests that such a reflex may have had an
effect on the costs and the outcomes.
Table 2 summarises the frequency of non-scheduled
angiograms and repeat revascularisation procedures in
patients with and without protocol mandated follow up
angiography in the BENESTENT II trial.4 The need for non-
scheduled angiography in each group is shown according to
the time of its occurrence before, during, or after the period in
which follow up angiograms were scheduled. There were no
significant differences in the relative risk ratios for non-
scheduled angiography in the stent and balloon arms in
BENESTENT II. As table 2 shows (pooled data of the balloon
and stent groups), protocol mandated angiographic follow up
had no significant effect on the risk of unscheduled
angiography during the first five months, and no correction
factor was applied for this period. However, between five and
seven months (period of the scheduled angiography),
patients with no protocol mandated angiography had
significantly more non-scheduled angiograms (increased by
a factor of 3.577) and fewer repeat procedures (reduced by a
factor of 0.387). Also, after seven months, the group with
protocol mandated angiography had more non-scheduled
angiograms, which were accordingly corrected by a factor of
2.146. After correction of the RAVEL data according to the
expected effects of angiographic follow up, the difference in
the number of repeat procedures was then estimated at 11.8%
instead of 23.6%. Moreover, the difference in the number of
unscheduled angiograms was estimated at 3.8% instead of
1.9%.
Table 3 shows the results from the regression analyses
relating the costs per patient to the costs of the initial
procedure and the occurrence of all MACE, other serious
adverse events, and angiograms (r2 = 0.35; F = 10.76;
F test p , 0.001). Applying the derived relative risks to the
patient specific data leads to the estimates of both costs and
effects as presented in table 4. Without routine angiographic
follow up the difference in costs between the sirolimus
eluting stent and the bare metal stent at one year was
estimated to be J166. The costs per additional MACE-free
survivor are now estimated to be J1495 with an upper 95%
limit of J61 243. Figure 1 presents the estimates of both
cost and effects after a combination of bootstrapping and
Table 3 Cost estimates derived from multivariate analyses relating the costs per patient to
the costs of the initial procedure, the occurrence of adverse events, and coronary
angiograms
Cost estimate (J) Standard error
Initial costs 5097 253
Additional costs of drug eluting stent 1360 311
Death* 1194 1197
Myocardial infarction 3693 788
Coronary bypass surgery 12147 1316
First repeat percutaneous intervention 4374 455
Additional repeat percutaneous intervention 6665 705
Non-scheduled angiography 3561 538
Other serious adverse events 4411 246
*Death was not a significant predictor.
Table 4 Costs and effects based on various scenarios
With angiographic follow up Without angiographic follow up
Sirolimus stent
(n = 120)
Bare stent
(n = 118) Difference
Sirolimus stent
(n = 120)
Bare stent
(n = 118) Difference
Clinical events
Death 1.7% 1.7% 0 1.7% 1.7% 0
Myocardial infarction 3.3% 5.1% 21.8% 3.3% 5.1% 21.8
Target lesion revascularisations 0.8% 23.6% 222.8% 0.8% 11.8% 211
Surgical 0.8% 0.8% 0 0.8% 0.3% 0.5
Percutaneous 0.0% 22.9% 222.9% 0.0 11.5% 211.5
MACE-free survival 94.2% 71.2% 23.0% 94.2% 83.1% 11.1%
95% CI 89.9 to 98.4 62.9 to 79.4 13.7 to 32.2 88.9 to 97.5 64.2 to 90.9 1.7 to 28.0
Angiography 8.3% 10.2% 21.9% 10.3% 14.1% 23.8%
Total direct medical cost (J) 9969 9915 54 8065 7899 166
95% CI 8910 to 10504 8722 to 10449 21054 to 1296 7052 to 9463 6821 to 9591 21376 to 1487
MACE, major adverse cardiac events.
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multivariate sensitivity analysis based on the normal
distributions surrounding the estimates of the relative risks.
DISCUSSION
In this report, we analysed the balance between costs and
effects in the RAVEL trial, while recognising the potential
increase in interventions due to the oculostenotic reflex
associated with protocol driven angiographic follow up. Two
scenarios were presented: one with scheduled angiographic
follow up, based on actual data from the RAVEL study, and
one that corrected for the effect of protocol driven angio-
grams. The first scenario led to an estimated cost difference at
the end of one year of J54 per patient and a cost per MACE-
free survivor of J234. The second scenario led to an
estimated cost difference of J166 at the end of one year
and a cost per MACE-free survivor of J1495. Both point
estimates seem to be well within a range of what may be
considered acceptable from a societal standpoint.
These results need to be assessed in light of the study
limitations. A first limitation is that the analysis was based
primarily on data from the RAVEL study, which included
only 238 patients with a primary end point of angiographic
late loss at six months; MACE and resource utilisation were
only secondary end points. Cost effectiveness was not a
formal end point, mainly because of protocol mandated
angiographic follow up, whose effect on outcomes was
adjusted based on the BENESTENT II study. Our analysis
of the costs and effects without angiographic follow up
therefore has at least three sources of uncertainty. Firstly,
there is the limited number of observations in the RAVEL
study. Secondly, there is the estimate of effects of the
oculostenotic reflex from the BENESTENT II study. Thirdly,
there is the estimate of the costs that need to be subtracted as
a result of this reflex. We considered all of these in our
estimate leading to an upper 95% limit of J61 243. These
numbers might have been even higher considering that the
patients in the BENESTENT II study differ from those in
RAVEL. The difference in MACE-free survival, considering
only the revascularisations that were labelled as being
clinically driven, was very close to that of the combined
analysis suggesting that this last potential source of error
may have been relatively small.
An alternative approach would have been to recalculate
costs and effects by excluding the events that were not
clinically driven. We decided against this approach, since it
would not account for the effects of the protocol driven
angiograms on the rate of clinically driven angiograms and
on the reintervention rate before month 5 and after month 7.
The RAVEL study included a relatively non-complex group
of patients, admitted for single lesion stenting (single vessel
disease in 71%) of short coronary stenosis (average lesion
length 9.58 mm). How the sirolimus eluting stent will
perform in other patient populations with different risks of
reintervention needs to be studied, in terms of not only
efficacy but also cost effectiveness. Moreover, the RAVEL was
an international study and no account was taken of
differences in treatment patterns. Unit costs were estimated
from one hospital and treated as if they were not surrounded
by uncertainty. It was noted that the estimated differences in
costs were highly dependent on the price difference between
the sirolimus stents (J2000) and the bare stents (J672). As
an example, when the price of the bare metal stent was set
around J500, as it is in the UK, the total one year cost
difference between the treatments was estimated at J341 in
favour of bare stents, instead of J166.
A final important limitation concerns the outcome of the
study. Sirolimus eluting stent implantation increased MACE-
free survival, which is a combined end point of death,
myocardial infarction, and repeat revascularisations. In
practice it may reduce the need only for revascularisa-
tions.1–3 10 Furthermore, it may be hypothesised that the anti-
restenotic effect of sirolimus stents may improve the rate of
recurrent ischaemic symptoms and quality of life parameters.
However, direct quality of life data have not been collected to
determine the extent of the potential benefit of sirolimus
stents in this regard. As such, cost per additional MACE-free
survivor may not be the optimal way of expressing the
balance between costs and effects in this scenario. In
addition, the results obtained by calculating costs per
MACE-free survivor, or costs per repeat procedure prevented,
cannot be compared with the results of other health care
interventions such as hip replacements. Given the lack of
comparable outcomes, one may well ask the question how
much society is prepared to pay to prevent repeat interven-
tion during the first year after the initial intervention.
However, when doing so, it may be important to recognise
that the burden associated with the need for a repeat
intervention may not be limited to a short period of anginal
pain; one should also consider increased anxiety, disability
and, most notably, an increased incidence of even more
hospitalisations, some of which may result in repeat
interventions.
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surrounding the estimates of the relative risks. MACE, major adverse cardiac events.
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Intracardiac extension of a large cell undifferentiated carcinoma of lung
A
60 year old male presented with complaints of cough,
dyspnoea, reduced appetite, and a history of 70 pound
(30 kg) weight loss over the previous year.
Chest radiograph showed complete opacification of the
left hemithorax with only minimal aeration of the most
cephaloid lung apex.
A computed tomographic (CT) scan (below left) of the
chest showed a 10 cm mass in the posterior left lower lobe
with invasion into the left atrium by way of the left inferior
pulmonary vein. There was left basilar lung atelactasis with a
small left pleural effusion. The panel shows the lung mass
and tumour extension into the left atrium (AL, atelactatic
lung; LA, left atrium; LV, left ventricle; RA, right atrium; RV,
right ventricle, T, tumour).
A bronchoscopy was performed. This showed complete
occlusion of the left main stem bronchus secondary to an
endobronchial lesion arising from the lower left bronchial tree.
Bronchoscopic biopsy was performed. This showed poorly
differentiated carcinoma with large, hyperchromatic,
pleomorphic nuclei with prominent nucleoli and coarse
chromatin (below right: haematoxylin and eosin, 640
magnification). The cells had pale, vacuolated cytoplasm
with indistinct cell borders. Features to suggest squamous
cell carcinoma, such as sharp cytoplasmic borders and
cytoplasmic keratinisation, were not seen. Features diagnos-
tic of adenocarcinoma, such as intracytoplasmic mucin,
glandular differentiation, and a papillary growth pattern,
were not identified. These findings were consistent with a
large cell undifferentiated carcinoma of lung.
The patient was treated with carboplatin and paclitaxel
chemotherapy.
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